Confirming these results, characterization of the microbiome of the local non-small cell lung cancer (NSCLC) by employing 16S rRNA gene amplicon sequencing of bronchoscopic tumor biopsies isolated from patients receiving PD-1/PD-L1-targeted immunotherapy showed high proportions of Bacteroidetes, Proteobacteria, and Firmicutes associated with prolonged OS of irrespective of the clinical response to progression-free survival (PFS) or ICI treatment [66]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.